• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PROPOXYPHENE Drug Record

  • Summary
  • Interactions
  • Claims
  • PROPOXYPHENE chembl:CHEMBL1213351

    Alternate Names:

    PROPOXYPHENE
    DEXTROPROPOXYPHENE
    LEVOPROPOXYPHENE
    DEXTROPROPOXYPHENUM
    (+)-1,2-DIPHENYL-2-PROPIONOXY-3-METHYL-4-DIMETHYLAMINOBUTANE
    (S)-ALPHA-(2-(DIMETHYLAMINO)-1-METHYLETHYL)-ALPHA-PHENYLBENZENEETHANOL PROPANOATE
    DEXTROPROPOXYPHEN
    4-DIMETHYLAMINO-3-METHYL-1,2-DIPHENYL-2-PROPOXYBUTANE
    DESTROPROPOSSIFENE
    (+)-ALPHA-PROPOXYPHENE
    DEXTROPROPOXYPHÈNE
    ALPHA-D-4-DIMETHYLAMINO-3-METHYL-1,2-DIPHENYL-2-BUTANOL-PROPIONAT
    ALPHA-(+)-4-DIMETHYLAMINO-1,2-DIPHENYL-3-METHYL-2-BUTANOL PROPIONATE ESTER
    DEXTROPROPOXIFENO
    (+)-4-DIMETHYLAMINO-1,2-DIPHENYL-3-METHYL-2-PROPIONYLOXYBUTANE
    DARVON®
    D-PROPOXYPHENE
    chembl:CHEMBL1213351
    chemidplus:469-62-5
    rxcui:8785
    pubchem.compound:10100
    drugbank:00647

    Drug Info:

    FDA Approval Approved before 1982
    Drug Class small molecule
    Drug Indications Antitussive Agents
    Drug Indications Analgesics, Opioid
    Drug Class antitussive agents
    Drug Class analgesics, opioid
    Year of Approval approved before 1982
    (2 More Sources)

    Publications:

    Picker, 1997, Discriminative stimulus effects of the mixed-opioid agonist/antagonist dezocine: cross-substitution by mu and delta opioid agonists., J. Pharmacol. Exp. Ther.
    Walker et al., 1999, Naltrexone and beta-funaltrexamine antagonism of the antinociceptive and response rate-decreasing effects of morphine, dezocine, and d-propoxyphene., Psychopharmacology (Berl.)
    Bannwarth et al., 2009, The dextropropoxyphene controversy., Joint Bone Spine
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Codd et al., 1995, Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception., J. Pharmacol. Exp. Ther.
    Tyers, 1980, A classification of opiate receptors that mediate antinociception in animals., Br. J. Pharmacol.
    Ulens et al., 1999, Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents., Cardiovasc. Res.
    Neil, 1984, Affinities of some common opioid analgesics towards four binding sites in mouse brain., Naunyn Schmiedebergs Arch. Pharmacol.
    Yin OQ et al., 2010, CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition., J Clin Pharmacol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • PROPOXYPHENE   OPRM1

    Interaction Score: 1.34

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    9399970 10379623 19604717 11752352 7562497 6249436 10690289


    Sources:
    TdgClinicalTrial TEND

  • PROPOXYPHENE   OPRD1

    Interaction Score: 1.13

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    6151117


    Sources:
    TdgClinicalTrial TEND

  • PROPOXYPHENE   OPRK1

    Interaction Score: 0.91

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11752352 6151117


    Sources:
    TdgClinicalTrial TEND

  • PROPOXYPHENE   CYP3A5

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20133509 18695978


    Sources:
    PharmGKB

  • TdgClinicalTrial: PROPOXYPHENE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Analgesics, Opioid
    Drug Indications Antitussive Agents
    Drug Class small molecule

    Publications:

  • TEND: PROPOXYPHENE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Year of Approval approved before 1982
    Drug Class analgesics, opioid
    Drug Class antitussive agents

    Publications:

  • PharmGKB: dextropropoxyphene

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yin OQ et al., 2010, CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition., J Clin Pharmacol

  • PharmGKB: propoxyphene

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

  • TTD: Dextropropoxyphene

    • Version: 2020.06.01

    Alternate Names:
    D0D4PB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1213351

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21